AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies
about
Effects of Ginkgo biloba on chemically-induced mammary tumors in rats receiving tamoxifenHSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerDown-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.The significance of heat shock proteins in breast cancer therapy.Endocrine resistance in breast cancer.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitSGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.
P2860
Q28703563-E87C9E57-46B7-4ED5-9ACF-14C372D5E023Q34793260-74F3BD82-1325-440B-9F93-84A6BAA4D821Q35128098-22659EAA-26A1-4BA6-B17E-8735072948E6Q35752065-B7C492CC-C14F-4D4F-9F28-FA78B9F4AD27Q36413297-1F0892A3-6230-4566-81E5-3500C3CD664DQ37690969-D32B8D62-388F-4B29-8ACD-F601E264CF7CQ38100745-959EA878-2E2C-447D-B1EB-27511F4B33BDQ38163573-941FA928-2CD0-4A65-9E97-C0A3791FAFB1Q39172020-DA570613-8F08-4999-9F53-2DF93898988FQ42154267-CC2C9125-11ED-4A63-8C82-146A3987882EQ42700000-0AD461F3-E506-45AB-8BD9-D22CC336836DQ55426345-F27710E7-F5F2-41E0-A331-F9CD82BFD367
P2860
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AKT-aro and HER2-aro, models f ...... and inhibitor response studies
@en
AKT-aro and HER2-aro, models f ...... nd inhibitor response studies.
@nl
type
label
AKT-aro and HER2-aro, models f ...... and inhibitor response studies
@en
AKT-aro and HER2-aro, models f ...... nd inhibitor response studies.
@nl
prefLabel
AKT-aro and HER2-aro, models f ...... and inhibitor response studies
@en
AKT-aro and HER2-aro, models f ...... nd inhibitor response studies.
@nl
P2093
P2860
P1476
AKT-aro and HER2-aro, models f ...... and inhibitor response studies
@en
P2093
Cynthie Wong
David Smith
Kaladhar Reddy
Shiuan Chen
P2860
P2888
P304
P356
10.1007/S10549-012-2105-6
P407
P577
2012-06-16T00:00:00Z